4. Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 2020;31:1056-...
3.Zhou C, Lu Y, et al. LBA11 Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve advanced ALK+ non small cell lung cancer (NSCLC): 5-year update from the phase III ALESIA study...
onclive.com/view/fda-ap [3]LBA2 ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC).DOI:doi.org/10.1016/j.annon PlumX Metrics [4]2023ESMO会议摘要.
参考文献 [1]Zhang Chao, Li Shao-Lei, Nie Qiang, et al. Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement. J Thorac Oncol, 2019, 14: 726-731. [2]Zhang C, Jiang BY, Yan LX, et al. Induction ALK-TKIs for stage III non-small cell ...
Preliminary safety and efficacy of iruplinalkib after chemoradiotherapy (CRT) in ALK/ROS1+ unresectable non-small cell lung cancer (NSCLC): Part 1 results from the INNOVATION study 伊鲁阿克对放化疗 (CRT) 后 ALK/ROS1+ 不可切除非小细胞肺癌的初步安全性和疗效: INNOVATION 研究的第一部分结果 ...
4、Shimizu J, Masago K, Saito H, et al. Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study)[J]. Therapeutic advances in medical...
4、Shimizu J, Masago K, Saito H, et al. Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study)[J]. Therapeutic advances in medical...
非小细胞肺癌与ALK、EGFR、HER2等抑制剂关系 - MCE 全球每年大约有 160 万人死于肺癌。根据细胞来源，约 80-85％是非小细胞肺癌 (NSCLC)。在组织学上，NSCLC 有几种亚型，包括肺腺癌 (LUAD)、肺鳞状细胞癌 (LUSC)、大细胞癌等。基因分型研究已经揭示了 NSCLC 各种亚型的遗传/分子异常，这些驱动致癌突变使癌...
non‐small‐cell lung cancer (NSCLC)The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse...
其中约85%为非小细胞肺癌(non-small cell lung cancer,NSCLC),15%为小细胞肺癌(Small cell lung cancer,SCLC)。 ALK基因融合 ALK基因融合在炎性成肌纤维母细胞瘤、非小细胞肺癌、乳腺癌、直结肠癌、食管鳞状上皮细胞癌、肾细胞癌、卵巢癌等实体肿瘤和淋巴瘤患者中均有报道;肺腺癌患者中ALK融合的发生率为3 ~...